Compare Microchip Technology Inc. (MCHP) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs GeneDx Holdings Corp — how do they compare? Microchip Technology Inc. trades at $73.78 (market cap $41.01B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: Microchip Technology Inc. is far larger — about 20.3× GeneDx Holdings Corp's market cap, and Microchip Technology Inc. pays a 2.41% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and GeneDx Holdings Corp for 19 Days on average.
| MCHP | WGS | |
|---|---|---|
Market Cap | $41.01B | $2.02B |
Volume | 9,972,516 | 734,640 |
Sector | Technology | Health |
52-Week High | $102.97 | $167.51 |
52-Week Low | $49.02 | $34.51 |
Typical Hold Time | 62 Days | 19 Days |
Enterprise Value | $46.13B | $2.05B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $74.00, down 5.15% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500,000 in 2025, a sharp decline from prior profitability, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in Ethernet and 48V power portfolios and the completion of the Hailo acquisition, targeting growth in automotive, industrial, and AI-driven data center markets.
Outlook: Strong analyst consensus (69.57% Buy) and a $110.50 price target suggest significant upside potential, driven by AI infrastructure demand and portfolio expansion. Key risks include high valuation multiples, substantial long-term debt of $5.63B, and sensitivity to semiconductor cycle volatility. Earnings recovery in 2026 forecasts is critical for sustaining investor confidence.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
